UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000012424
Receipt number R000014543
Scientific Title Safety and efficacy of L-carnitine supplementation in patients with hematopoietic stem cell transplantation
Date of disclosure of the study information 2013/11/27
Last modified on 2018/12/03 09:29:32

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Safety and efficacy of L-carnitine supplementation in patients with hematopoietic stem cell transplantation

Acronym

L-carnitine supplementation for hematopoietic stem cell transplantation

Scientific Title

Safety and efficacy of L-carnitine supplementation in patients with hematopoietic stem cell transplantation

Scientific Title:Acronym

L-carnitine supplementation for hematopoietic stem cell transplantation

Region

Japan


Condition

Condition

Hematological malignancy, Bone marrow failure syndrome

Classification by specialty

Hematology and clinical oncology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

The purpose of this study is to determine the safety and efficacy of L-carnitine supplementation in patients with stem cell transplantation.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

The change in average fatigue from baseline to day100

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit


Blinding

Open -but assessor(s) are blinded

Control

No treatment

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

L-carnitine supplementation

Interventions/Control_2

No carnitine supplementation

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

65 years-old >

Gender

Male and Female

Key inclusion criteria

Eligibility criteria included 20 years of age or older. All patients need possiblility of survival of more than 3 months from the time of registration and written informed consent.

Key exclusion criteria

Exclusion criteria included intake of carnitine in the last two months, carnitine allergy, severe complications, pregnancy, severe mental illness.

Target sample size

30


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Satoshi Iyama

Organization

Sapporo Medical University School of Medicine

Division name

Department of Medical Oncology and Hematology

Zip code


Address

South-1 West-16, Chuo-ku, Sapporo, Japan

TEL

011-611-2111

Email

iyama@sapmed.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Satoshi Iyama

Organization

Sapporo Medical University School of Medicine

Division name

Department of Medical Oncology and Hematology

Zip code


Address

South-1 West-16, Chuo-ku, Sapporo, Japan

TEL

011-611-2111

Homepage URL


Email

iyama@sapmed.ac.jp


Sponsor or person

Institute

Sapporo Medical University School of Medicine, Department of Medical Oncology and Hematology

Institute

Department

Personal name



Funding Source

Organization

Sapporo Medical University School of Medicine, Department of Medical Oncology and Hematology

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2013 Year 11 Month 27 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2013 Year 09 Month 24 Day

Date of IRB


Anticipated trial start date

2013 Year 11 Month 27 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2013 Year 11 Month 27 Day

Last modified on

2018 Year 12 Month 03 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000014543


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name